

May 2, 2020

Listing Department  
**BSE Limited**  
P J Towers, Dalal Street, Fort,  
Mumbai – 400001

**Code: 532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400051

**Code: CADILAH**

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated May 2, 2020 titled “Zydus receives tentative approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

## Zydus receives tentative approval from USFDA for Empagliflozin and Metformin Hydrochloride Tablets

---

Ahmedabad, May 2, 2020

Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin and Metformin Hydrochloride Tablets, 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg (US RLD: Synjardy™ Tablets)

A combination of 2 drugs: empagliflozin and metformin, this medication is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. It will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad.

The group now has 289 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

### About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*